More Argent Biopharma Ltd news
Argent Biopharma LtdASX: RGT

Further findings on ArtemiC as anti-inflammatory agent

May 7, 2021 at 6:33 AM EDT · Issued by Argent Biopharma Ltd

Filed with ASX · May 7, 2021 at 6:33 AM EDT · 5 pages · English

On 6ix: 6ix.com/news/further-findings-on-artemic-as-anti-inflammatory-agent

Argent Biopharma Ltd on 6ix

Story so far

  • $1M order for ArtemiC Rescue from swiss PharmaCanMay 4, 2021
  • ArtemiC submitted to Health CanadaApr 28, 2021
  • Mxc completes first ArtemiC order, March qtr record revenueApr 7, 2021

Earlier from Argent Biopharma

  • $1M order for ArtemiC Rescue from swiss PharmaCanMay 3, 2021
  • ArtemiC submitted to Health CanadaApr 28, 2021
  • March quarterly activity and cashflow reportApr 26, 2021
  • MGC pharma to acquire medical research company MediCaNLApr 21, 2021
  • Investor presentationApr 9, 2021

Later from Argent Biopharma

  • CimetrA patent submitted to European IP officeMay 17, 2021
  • MGC pharma 2021 clinical trials program updateMay 24, 2021
  • CannEpil available for free dispensing in irelandJun 14, 2021
  • 1St patient recruited into CimetrA phase 3 clinical trialJul 12, 2021
  • Patent application lodged for novel drug delivery systemJul 15, 2021
All Argent Biopharma news releases↗

Follow Argent Biopharma into a list and get an email when it puts out news.

Follow Argent Biopharma
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer